5 citations
,
January 2018 in “PubMed” In this study, applying a biodegradable microneedle patch after topical steroid application significantly increased steroid penetration and improved treatment outcomes in patients with prurigo nodularis compared to the control.
2 citations
,
October 2023 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” This case report found that dupilumab treatment in a 5-year-old with prurigo nodularis considerably reduced her itch severity and nearly cleared the skin lesions after six months.
July 2026 in “Frontiers in Immunology” In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.
April 2026 in “Clinical and Experimental Dermatology” This study found that treating moderate-to-severe prurigo nodularis with dupilumab significantly improved itch severity, skin condition, and quality of life over 104 weeks, with a favorable safety profile, even in elderly and comorbid patients.
April 2026 in “Expert Opinion on Biological Therapy” This review discusses prurigo nodularis and reports no new results, emphasizing the need for further research into its pathophysiology and treatment options.